[
  {
    "id": "who-surgical-safety",
    "category": "safety",
    "titles": {
      "fr": "Checklist de sécurité chirurgicale OMS",
      "en": "WHO Surgical Safety Checklist",
      "pt": "Checklist de segurança cirúrgica OMS"
    },
    "steps": {
      "fr": [
        "SIGN IN (avant induction): confirmer identité, site opératoire, intervention, consentement",
        "Vérifier marquage du site chirurgical",
        "Contrôle de sécurité de l'appareil d'anesthésie et médicaments",
        "Oxymètre de pouls fonctionnel sur le patient",
        "Allergie connue? Voie aérienne difficile? Risque hémorragique?",
        "TIME OUT (avant incision): tous les membres se présentent",
        "Confirmer patient, site, procédure",
        "Antibioprophylaxie administrée dans les 60 dernières minutes?",
        "Imagerie disponible? Événements critiques anticipés?",
        "SIGN OUT (avant sortie de salle): nom de l'intervention enregistré",
        "Comptage instruments, compresses, aiguilles — correct",
        "Étiquetage prélèvements anatomopathologiques",
        "Problèmes d'équipement à signaler?",
        "Points clés pour la prise en charge postopératoire"
      ],
      "en": [
        "SIGN IN (before induction): confirm identity, site, procedure, consent",
        "Verify surgical site marking",
        "Anesthesia machine and medication safety check",
        "Pulse oximeter on patient and functioning",
        "Known allergy? Difficult airway? Bleeding risk?",
        "TIME OUT (before incision): all team members introduce themselves",
        "Confirm patient, site, procedure",
        "Antibiotic prophylaxis given within last 60 minutes?",
        "Imaging displayed? Critical events anticipated?",
        "SIGN OUT (before leaving OR): procedure name recorded",
        "Instrument, sponge, needle count — correct",
        "Specimen labeling",
        "Equipment problems to report?",
        "Key concerns for postoperative care"
      ],
      "pt": [
        "SIGN IN (antes da indução): confirmar identidade, local, intervenção, consentimento",
        "Verificar marcação do local cirúrgico",
        "Controlo de segurança do aparelho de anestesia e medicamentos",
        "Oxímetro de pulso no doente e a funcionar",
        "Alergia conhecida? Via aérea difícil? Risco hemorrágico?",
        "TIME OUT (antes da incisão): todos os membros se apresentam",
        "Confirmar doente, local, procedimento",
        "Antibioterapia profilática administrada nos últimos 60 minutos?",
        "Imagiologia disponível? Eventos críticos antecipados?",
        "SIGN OUT (antes de sair da sala): nome da intervenção registado",
        "Contagem de instrumentos, compressas, agulhas — correta",
        "Etiquetagem de amostras anatomopatológicas",
        "Problemas de equipamento a reportar?",
        "Pontos chave para cuidados pós-operatórios"
      ]
    },
    "references": [
      { "source": "WHO Surgical Safety Checklist", "year": 2009 },
      { "source": "Haynes AB et al. NEJM", "year": 2009 }
    ]
  },
  {
    "id": "ponv-protocol",
    "category": "ponv",
    "titles": {
      "fr": "Protocole NVPO (nausées-vomissements postopératoires)",
      "en": "PONV Protocol",
      "pt": "Protocolo NVPO"
    },
    "steps": {
      "fr": [
        "1. Évaluer le score d'Apfel en préopératoire",
        "2. Risque faible (0-1 facteurs): pas de prophylaxie systématique",
        "3. Risque modéré (2 facteurs): dexaméthasone 4-8mg IV à l'induction",
        "4. Risque élevé (3-4 facteurs): bithérapie dexaméthasone 4-8mg + ondansétron 4mg fin de chirurgie",
        "5. Considérer TIVA propofol si risque élevé",
        "6. Analgésie multimodale pour réduire les opioïdes",
        "7. Traitement de secours en SSPI: ondansétron 4mg IV si pas déjà reçu",
        "8. Si prophylaxie déjà reçue: utiliser une AUTRE classe (dropéridol 0.625mg, métoclopramide 10mg)",
        "9. Documentation systématique du score NVPO et traitement dans le dossier"
      ],
      "en": [
        "1. Assess Apfel score preoperatively",
        "2. Low risk (0-1 factors): no routine prophylaxis",
        "3. Moderate risk (2 factors): dexamethasone 4-8mg IV at induction",
        "4. High risk (3-4 factors): dual therapy dexamethasone 4-8mg + ondansetron 4mg end of surgery",
        "5. Consider TIVA propofol if high risk",
        "6. Multimodal analgesia to reduce opioids",
        "7. Rescue in PACU: ondansetron 4mg IV if not already given",
        "8. If prophylaxis already given: use DIFFERENT class (droperidol 0.625mg, metoclopramide 10mg)",
        "9. Systematic documentation of PONV score and treatment"
      ],
      "pt": [
        "1. Avaliar score de Apfel no pré-operatório",
        "2. Risco baixo (0-1 fatores): sem profilaxia de rotina",
        "3. Risco moderado (2 fatores): dexametasona 4-8mg IV na indução",
        "4. Risco alto (3-4 fatores): terapia dupla dexametasona 4-8mg + ondansetron 4mg no fim da cirurgia",
        "5. Considerar TIVA propofol se risco alto",
        "6. Analgesia multimodal para reduzir opióides",
        "7. Resgate na UCPA: ondansetron 4mg IV se ainda não administrado",
        "8. Se profilaxia já feita: usar OUTRA classe (droperidol 0.625mg, metoclopramida 10mg)",
        "9. Documentação sistemática do score NVPO e tratamento"
      ]
    },
    "references": [{ "source": "Consensus Guidelines on PONV (Gan et al.)", "year": 2020 }],
    "tags": ["ponv", "apfel", "antiemetic", "rescue"],
    "source": "Consensus PONV",
    "version": "2025.1",
    "published_at": "2025-02-01T00:00:00Z",
    "review_at": "2027-02-01T00:00:00Z",
    "evidence_grade": "A"
  },
  {
    "id": "ponv-risk-prophylaxis",
    "category": "ponv",
    "titles": {
      "fr": "NVPO: conduite pratique par niveau de risque",
      "en": "PONV: practical management by risk level",
      "pt": "NVPO: conduta prática por nível de risco"
    },
    "steps": {
      "fr": [
        "1. Calculer le score d'Apfel et noter le niveau de risque avant l'induction",
        "2. Si 0-1 facteur: pas de prophylaxie systématique, limiter halogénés et morphiniques si possible",
        "3. Si 2 facteurs: choisir UNE option (dexaméthasone 4-8 mg IV à l'induction OU ondansétron 4 mg IV en fin d'intervention)",
        "4. Si 3 facteurs: bithérapie (dexaméthasone + ondansétron) et stratégie d'épargne opioïde obligatoire",
        "5. Si 4 facteurs ou antécédent sévère: TIVA propofol + bithérapie + plan de secours anticipé",
        "6. En SSPI: si nausées malgré prophylaxie, choisir une classe non encore utilisée (dropéridol, métoclopramide, autre 5-HT3 selon délai)",
        "7. Avant sortie: vérifier hydratation, douleur contrôlée, absence de vomissements répétés et documenter le traitement"
      ],
      "en": [
        "1. Calculate Apfel score and record the risk level before induction",
        "2. If 0-1 factor: no routine prophylaxis, reduce volatile agents and opioids whenever possible",
        "3. If 2 factors: choose ONE option (dexamethasone 4-8 mg IV at induction OR ondansetron 4 mg IV at the end of surgery)",
        "4. If 3 factors: dual therapy (dexamethasone + ondansetron) and an opioid-sparing plan are required",
        "5. If 4 factors or severe history: propofol TIVA + dual therapy + pre-planned rescue strategy",
        "6. In PACU: if symptoms occur despite prophylaxis, use a class not yet given (droperidol, metoclopramide, another 5-HT3 depending on timing)",
        "7. Before discharge: confirm hydration, pain control, no repeated vomiting and document the treatment"
      ],
      "pt": [
        "1. Calcular o score de Apfel e registar o nível de risco antes da indução",
        "2. Se 0-1 fator: sem profilaxia de rotina, reduzir halogenados e opióides sempre que possível",
        "3. Se 2 fatores: escolher UMA opção (dexametasona 4-8 mg IV na indução OU ondansetron 4 mg IV no fim da cirurgia)",
        "4. Se 3 fatores: terapêutica dupla (dexametasona + ondansetron) e plano de poupança de opióides obrigatório",
        "5. Se 4 fatores ou antecedente grave: TIVA com propofol + terapêutica dupla + estratégia de resgate previamente definida",
        "6. Na UCPA: se houver sintomas apesar da profilaxia, usar classe ainda não administrada (droperidol, metoclopramida, outro 5-HT3 conforme o timing)",
        "7. Antes da alta: confirmar hidratação, dor controlada, ausência de vómitos repetidos e documentar o tratamento"
      ]
    },
    "references": [
      {
        "source": "Fourth Consensus Guidelines for the Management of PONV",
        "year": 2020,
        "doi": "10.1213/ANE.0000000000004833"
      }
    ],
    "tags": ["ponv", "apfel", "ambulatory", "rescue"],
    "source": "Consensus PONV",
    "version": "2025.1",
    "published_at": "2025-02-01T00:00:00Z",
    "review_at": "2027-02-01T00:00:00Z",
    "evidence_grade": "A"
  },
  {
    "id": "difficult-airway-algorithm",
    "category": "safety",
    "titles": {
      "fr": "Algorithme VAD / CICO adulte",
      "en": "Adult difficult airway / CICO algorithm",
      "pt": "Algoritmo de via aérea difícil / CICO no adulto"
    },
    "steps": {
      "fr": [
        "1. Avant induction: briefing, plan A/B/C, appel d'aide précoce, chariot VAD ouvert, capnographie et aspiration vérifiées",
        "2. Préoxygéner de façon optimale (masque étanche, PEEP si besoin, position tête surélevée)",
        "3. Plan A: 1re tentative la plus compétente avec vidéo-laryngoscope si disponible, limiter à 2 tentatives optimisées",
        "4. Si échec: réoxygéner, corriger position, lame, mandrin, BURP, puis décider rapidement si une 2e tentative est défendable",
        "5. Plan B: dispositif supraglottique de 2e génération, confirmer EtCO2, ventiler et décider réveil / poursuite / intubation via dispositif",
        "6. Si oxygénation impossible: déclarer CICO à voix haute, demander matériel de front-of-neck access, poursuivre oxygénation maximale",
        "7. Plan C: cricothyroïdotomie scalpel-bougie-tube selon protocole local, puis confirmer EtCO2 et stabiliser l'hémodynamique",
        "8. Après l'événement: tracer la difficulté, informer l'équipe et le patient, sécuriser le plan pour les anesthésies futures"
      ],
      "en": [
        "1. Before induction: team brief, plan A/B/C, early call for help, difficult airway cart open, capnography and suction checked",
        "2. Preoxygenate optimally (tight mask seal, PEEP if needed, head-up positioning)",
        "3. Plan A: first attempt by the most experienced operator, use video laryngoscopy if available, limit to 2 optimized attempts",
        "4. If unsuccessful: reoxygenate, correct position, blade, stylet, external laryngeal manipulation, then decide fast whether a second attempt is justified",
        "5. Plan B: 2nd-generation supraglottic device, confirm EtCO2, ventilate and decide wake-up / proceed / intubate through device",
        "6. If oxygenation fails: declare CICO out loud, request front-of-neck access kit, continue maximal oxygenation efforts",
        "7. Plan C: scalpel-bougie-tube cricothyrotomy according to local protocol, then confirm EtCO2 and stabilize hemodynamics",
        "8. After the event: document the airway difficulty, debrief the team and patient, define the future airway plan"
      ],
      "pt": [
        "1. Antes da indução: briefing de equipa, plano A/B/C, pedido precoce de ajuda, carro de via aérea difícil aberto, capnografia e aspiração verificadas",
        "2. Pré-oxigenar de forma ótima (máscara selada, PEEP se necessário, posição com cabeça elevada)",
        "3. Plano A: primeira tentativa pelo operador mais experiente, videolaringoscópio se disponível, limitar a 2 tentativas otimizadas",
        "4. Se falhar: reoxigenar, corrigir posição, lâmina, mandril, manipulação laríngea externa, e decidir rapidamente se a 2ª tentativa é justificável",
        "5. Plano B: dispositivo supraglótico de 2ª geração, confirmar EtCO2, ventilar e decidir despertar / prosseguir / intubar através do dispositivo",
        "6. Se a oxigenação falhar: declarar CICO em voz alta, pedir kit de acesso anterior ao pescoço, manter esforço máximo de oxigenação",
        "7. Plano C: cricotirotomia scalpel-bougie-tube segundo protocolo local, depois confirmar EtCO2 e estabilizar hemodinamicamente",
        "8. Após o evento: documentar a dificuldade, fazer debrief da equipa e do doente, definir o plano para futuras anestesias"
      ]
    },
    "references": [
      {
        "source": "DAS 2015 unanticipated difficult intubation guidelines",
        "year": 2015,
        "doi": "10.1111/anae.13101"
      },
      {
        "source": "ASA 2022 Difficult Airway Guidelines",
        "year": 2022,
        "url": "https://pubs.asahq.org/anesthesiology/article/136/1/31/117915"
      }
    ],
    "tags": ["airway", "difficult_airway", "cico", "videolaryngoscope", "rescue"],
    "source": "DAS / ASA",
    "version": "2025.1",
    "published_at": "2025-01-15T00:00:00Z",
    "review_at": "2027-01-15T00:00:00Z",
    "evidence_grade": "A"
  },
  {
    "id": "massive-hemorrhage",
    "category": "emergency",
    "titles": {
      "fr": "Protocole d'hémorragie massive",
      "en": "Massive Hemorrhage Protocol",
      "pt": "Protocolo de hemorragia maciça"
    },
    "steps": {
      "fr": [
        "1. ALERTER: activer le protocole de transfusion massive (PTM)",
        "2. Remplissage: cristalloïdes balancés en urgence, puis sang O négatif si immédiat",
        "3. Prélèvements urgents: NFS, coagulation, fibrinogène, ionogramme, gazométrie",
        "4. Acide tranexamique 1g IV en 10 min dès le diagnostic",
        "5. Ratio transfusionnel: CGR:PFC:Plaquettes = 1:1:1 ou 2:1:1",
        "6. Objectifs: Hb > 7 g/dL, fibrinogène > 1.5 g/L, plaquettes > 50 000, TP > 40%",
        "7. Fibrinogène concentré 3-4g si fibrinogène < 1.5 g/L",
        "8. Calcium: maintenir Ca²⁺ ionisé > 1.0 mmol/L (citrate des PSL)",
        "9. Réchauffer patient et produits sanguins",
        "10. Réévaluer toutes les 30-60 min avec biologie de contrôle",
        "11. Considérer chirurgie de damage control si coagulopathie réfractaire"
      ],
      "en": [
        "1. ALERT: activate massive transfusion protocol (MTP)",
        "2. Resuscitation: balanced crystalloids, then O-negative blood if immediate need",
        "3. Urgent labs: CBC, coagulation, fibrinogen, electrolytes, ABG",
        "4. Tranexamic acid 1g IV over 10 min once diagnosed",
        "5. Transfusion ratio: RBC:FFP:Platelets = 1:1:1 or 2:1:1",
        "6. Targets: Hb > 7 g/dL, fibrinogen > 1.5 g/L, platelets > 50,000, PT > 40%",
        "7. Concentrated fibrinogen 3-4g if fibrinogen < 1.5 g/L",
        "8. Calcium: maintain Ca²⁺ ionized > 1.0 mmol/L (citrate from blood products)",
        "9. Warm patient and blood products",
        "10. Reassess every 30-60 min with repeat labs",
        "11. Consider damage control surgery if refractory coagulopathy"
      ],
      "pt": [
        "1. ALERTAR: ativar protocolo de transfusão maciça (PTM)",
        "2. Reposição: cristalóides balanceados em urgência, depois sangue O negativo se imediato",
        "3. Análises urgentes: hemograma, coagulação, fibrinogénio, ionograma, gasimetria",
        "4. Ácido tranexâmico 1g IV em 10 min ao diagnóstico",
        "5. Ratio transfusional: CE:PFC:Plaquetas = 1:1:1 ou 2:1:1",
        "6. Objetivos: Hb > 7 g/dL, fibrinogénio > 1.5 g/L, plaquetas > 50.000, TP > 40%",
        "7. Fibrinogénio concentrado 3-4g se fibrinogénio < 1.5 g/L",
        "8. Cálcio: manter Ca²⁺ ionizado > 1.0 mmol/L (citrato dos PSL)",
        "9. Aquecer doente e produtos sanguíneos",
        "10. Reavaliar a cada 30-60 min com biologia de controlo",
        "11. Considerar cirurgia de damage control se coagulopatia refratária"
      ]
    },
    "references": [
      { "source": "European Guidelines on Perioperative Bleeding", "year": 2023 },
      { "source": "SFAR RFE Hémorragie massive", "year": 2019 }
    ]
  },
  {
    "id": "or-safety",
    "category": "safety",
    "titles": {
      "fr": "Sécurité au bloc opératoire",
      "en": "Operating Room Safety",
      "pt": "Segurança no bloco operatório"
    },
    "steps": {
      "fr": [
        "1. Vérifier l'appareil d'anesthésie au début de chaque journée (checklist constructeur)",
        "2. Test d'étanchéité du circuit",
        "3. Vérifier l'aspiration murale fonctionnelle",
        "4. Chariot d'intubation difficile: vérifié et scellé",
        "5. Chariot d'urgence: défibrillateur, médicaments d'urgence vérifiés",
        "6. Vérifier les alarmes du monitorage (limites SpO2, PA, FC)",
        "7. Identification des médicaments: étiquetage systématique (norme ISO)",
        "8. Bracelet d'identification patient vérifié",
        "9. Positionnement du patient: prévention des lésions nerveuses et escarres",
        "10. Communication structurée (SBAR) entre équipes"
      ],
      "en": [
        "1. Check anesthesia machine at start of each day (manufacturer checklist)",
        "2. Circuit leak test",
        "3. Verify functional wall suction",
        "4. Difficult airway cart: checked and sealed",
        "5. Emergency cart: defibrillator, emergency drugs verified",
        "6. Verify monitoring alarms (SpO2, BP, HR limits)",
        "7. Drug identification: systematic labeling (ISO standard)",
        "8. Patient ID bracelet verified",
        "9. Patient positioning: prevention of nerve injury and pressure sores",
        "10. Structured communication (SBAR) between teams"
      ],
      "pt": [
        "1. Verificar aparelho de anestesia no início de cada dia (checklist do fabricante)",
        "2. Teste de estanquicidade do circuito",
        "3. Verificar aspiração de parede funcional",
        "4. Carro de via aérea difícil: verificado e selado",
        "5. Carro de emergência: desfibrilhador, medicamentos de emergência verificados",
        "6. Verificar alarmes da monitorização (limites SpO2, PA, FC)",
        "7. Identificação de medicamentos: etiquetagem sistemática (norma ISO)",
        "8. Pulseira de identificação do doente verificada",
        "9. Posicionamento do doente: prevenção de lesões nervosas e escaras",
        "10. Comunicação estruturada (SBAR) entre equipas"
      ]
    },
    "references": [
      { "source": "AAGBI Safety Guidelines", "year": 2020 },
      { "source": "HAS Checklist Bloc Opératoire", "year": 2018 }
    ]
  },
  {
    "id": "preop-fasting-protocol",
    "category": "preop",
    "titles": {
      "fr": "Protocole de jeûne préopératoire",
      "en": "Preoperative Fasting Protocol",
      "pt": "Protocolo de jejum pré-operatório"
    },
    "steps": {
      "fr": [
        "1. Liquides clairs (eau, thé, café noir, jus sans pulpe): autorisés jusqu'à 2h avant",
        "2. Lait maternel: autorisé jusqu'à 4h avant",
        "3. Repas léger: autorisé jusqu'à 6h avant l'intervention",
        "4. Repas riche en graisses: 8h de jeûne minimum",
        "5. Médicaments: pris avec une gorgée d'eau le matin (sauf indication contraire)",
        "6. ERAS: boisson glucidique (maltodextrine 12.5%) 400 mL la veille + 200 mL 2h avant",
        "7. Contre-indication ERAS: diabète insulino-traité, gastroparésie, RGO sévère",
        "8. Si estomac plein: ISR obligatoire, documenter le risque"
      ],
      "en": [
        "1. Clear liquids (water, tea, black coffee, pulp-free juice): allowed up to 2h before",
        "2. Breast milk: allowed up to 4h before",
        "3. Light meal: allowed up to 6h before surgery",
        "4. High-fat meal: minimum 8h fasting",
        "5. Medications: taken with a sip of water in the morning (unless otherwise indicated)",
        "6. ERAS: carbohydrate drink (maltodextrin 12.5%) 400 mL night before + 200 mL 2h before",
        "7. ERAS contraindication: insulin-treated diabetes, gastroparesis, severe GERD",
        "8. If full stomach: RSI mandatory, document the risk"
      ],
      "pt": [
        "1. Líquidos claros (água, chá, café sem leite, sumo sem polpa): permitidos até 2h antes",
        "2. Leite materno: permitido até 4h antes",
        "3. Refeição ligeira: permitida até 6h antes da intervenção",
        "4. Refeição rica em gorduras: mínimo 8h de jejum",
        "5. Medicamentos: tomar com gole de água de manhã (salvo indicação contrária)",
        "6. ERAS: bebida glicídica (maltodextrina 12.5%) 400 mL na véspera + 200 mL 2h antes",
        "7. Contra-indicação ERAS: diabetes insulino-tratada, gastroparésia, RGE grave",
        "8. Se estômago cheio: ISR obrigatória, documentar o risco"
      ]
    },
    "references": [{ "source": "ESA Preoperative Fasting Guidelines", "year": 2022 }]
  },
  {
    "id": "malignant-hyperthermia",
    "category": "emergency",
    "titles": {
      "fr": "Hyperthermie maligne (protocole d'urgence)",
      "en": "Malignant Hyperthermia (emergency protocol)",
      "pt": "Hipertermia maligna (protocolo de emergência)"
    },
    "steps": {
      "fr": [
        "1. SUSPECTER: rigidité musculaire, tachycardie, hypercapnie inexpliquée, hyperthermie rapide",
        "2. ARRÊTER immédiatement tous les agents déclencheurs (halogénés, succinylcholine)",
        "3. Hyperventiler à FiO2 100% avec débit de gaz frais ≥ 10 L/min",
        "4. DANTROLÈNE 2.5 mg/kg IV bolus, répéter chaque 5 min jusqu'à régression (max ~10 mg/kg)",
        "5. Refroidissement actif: solutés froids IV, glace axillaire/inguinale, lavage gastrique froid",
        "6. Traiter hyperkaliémie: bicarbonate, glucose-insuline, calcium",
        "7. Traiter arythmies (éviter bloqueurs calciques avec dantrolène)",
        "8. Monitorage: gazométrie, K+, CK, myoglobine, diurèse horaire",
        "9. Assurer diurèse > 2 mL/kg/h (prévention IRA myoglobinurique)",
        "10. Transférer en réanimation pour surveillance ≥ 24-48h",
        "11. Signaler au centre de référence et proposer diagnostic familial"
      ],
      "en": [
        "1. SUSPECT: muscle rigidity, tachycardia, unexplained hypercapnia, rapid hyperthermia",
        "2. STOP immediately all triggering agents (volatiles, succinylcholine)",
        "3. Hyperventilate at FiO2 100% with fresh gas flow ≥ 10 L/min",
        "4. DANTROLENE 2.5 mg/kg IV bolus, repeat every 5 min until regression (max ~10 mg/kg)",
        "5. Active cooling: cold IV fluids, axillary/inguinal ice, cold gastric lavage",
        "6. Treat hyperkalemia: bicarbonate, glucose-insulin, calcium",
        "7. Treat arrhythmias (avoid calcium channel blockers with dantrolene)",
        "8. Monitoring: ABG, K+, CK, myoglobin, hourly urine output",
        "9. Ensure urine output > 2 mL/kg/h (prevent myoglobinuric AKI)",
        "10. Transfer to ICU for monitoring ≥ 24-48h",
        "11. Report to reference center and offer family screening"
      ],
      "pt": [
        "1. SUSPEITAR: rigidez muscular, taquicardia, hipercapnia inexplicada, hipertermia rápida",
        "2. PARAR imediatamente todos os agentes desencadeadores (halogenados, succinilcolina)",
        "3. Hiperventilar a FiO2 100% com fluxo de gás fresco ≥ 10 L/min",
        "4. DANTROLENO 2.5 mg/kg IV bólus, repetir a cada 5 min até regressão (máx ~10 mg/kg)",
        "5. Arrefecimento ativo: soluções frias IV, gelo axilar/inguinal, lavagem gástrica fria",
        "6. Tratar hipercaliemia: bicarbonato, glicose-insulina, cálcio",
        "7. Tratar arritmias (evitar bloqueadores de cálcio com dantroleno)",
        "8. Monitorização: gasimetria, K+, CK, mioglobina, diurese horária",
        "9. Assegurar diurese > 2 mL/kg/h (prevenção IRA mioglobinúrica)",
        "10. Transferir para UCI para vigilância ≥ 24-48h",
        "11. Reportar ao centro de referência e propor diagnóstico familiar"
      ]
    },
    "references": [
      { "source": "MHAUS Guidelines", "year": 2023 },
      { "source": "SFAR Protocole HM", "year": 2019 }
    ]
  },
  {
    "id": "anaphylaxis",
    "category": "emergency",
    "titles": {
      "fr": "Anaphylaxie peropératoire (protocole d'urgence)",
      "en": "Perioperative Anaphylaxis (emergency protocol)",
      "pt": "Anafilaxia perioperatória (protocolo de emergência)"
    },
    "steps": {
      "fr": [
        "1. RECONNAÎTRE: hypotension brutale, bronchospasme, urticaire/érythème, tachycardie",
        "2. ARRÊTER l'agent suspecté, appeler à l'aide",
        "3. Adrénaline IV: Grade II 10-20 µg, Grade III 100-200 µg, Grade IV 1-2 mg",
        "4. Remplissage rapide cristalloïdes 20-30 mL/kg",
        "5. FiO2 100%, ventilation adaptée (bronchospasme: pression augmentée)",
        "6. Trendelenburg si hypotension",
        "7. Adrénaline en perfusion continue si instabilité persistante",
        "8. Bronchospasme réfractaire: salbutamol IV ou nébulisé",
        "9. Prélèvements: tryptase à T0, T1h, T24h + histamine si possible",
        "10. Corticoïdes: méthylprednisolone 1-2 mg/kg (prévention réaction biphasique)",
        "11. Surveillance ≥ 6-24h, bilan allergologique dans 4-6 semaines"
      ],
      "en": [
        "1. RECOGNIZE: sudden hypotension, bronchospasm, urticaria/erythema, tachycardia",
        "2. STOP suspected agent, call for help",
        "3. Epinephrine IV: Grade II 10-20 µg, Grade III 100-200 µg, Grade IV 1-2 mg",
        "4. Rapid crystalloid bolus 20-30 mL/kg",
        "5. FiO2 100%, adapted ventilation (bronchospasm: increased pressure)",
        "6. Trendelenburg if hypotensive",
        "7. Epinephrine infusion if persistent instability",
        "8. Refractory bronchospasm: IV or nebulized salbutamol",
        "9. Blood samples: tryptase at T0, T1h, T24h + histamine if possible",
        "10. Corticosteroids: methylprednisolone 1-2 mg/kg (prevent biphasic reaction)",
        "11. Monitoring ≥ 6-24h, allergy workup in 4-6 weeks"
      ],
      "pt": [
        "1. RECONHECER: hipotensão súbita, broncoespasmo, urticária/eritema, taquicardia",
        "2. PARAR o agente suspeito, pedir ajuda",
        "3. Adrenalina IV: Grau II 10-20 µg, Grau III 100-200 µg, Grau IV 1-2 mg",
        "4. Reposição rápida cristalóides 20-30 mL/kg",
        "5. FiO2 100%, ventilação adaptada (broncoespasmo: pressão aumentada)",
        "6. Trendelenburg se hipotensão",
        "7. Adrenalina em perfusão contínua se instabilidade persistente",
        "8. Broncoespasmo refratário: salbutamol IV ou nebulizado",
        "9. Colheitas: triptase a T0, T1h, T24h + histamina se possível",
        "10. Corticóides: metilprednisolona 1-2 mg/kg (prevenção reação bifásica)",
        "11. Vigilância ≥ 6-24h, estudo alergológico em 4-6 semanas"
      ]
    },
    "references": [
      { "source": "SFAR RFE Anaphylaxie périopératoire", "year": 2016 },
      { "source": "NAP6 - Anaphylaxis in Anaesthesia", "year": 2018 }
    ]
  },
  {
    "id": "antibioprophylaxis-protocol",
    "category": "preop",
    "titles": {
      "fr": "Protocole d'antibioprophylaxie",
      "en": "Antibiotic Prophylaxis Protocol",
      "pt": "Protocolo de antibioterapia profilática"
    },
    "steps": {
      "fr": [
        "1. Identifier le type de chirurgie (propre, propre-contaminée, contaminée)",
        "2. Injection 30-60 minutes avant l'incision (idéalement à l'induction)",
        "3. Chirurgie propre standard: céfazoline 2g IV (3g si ≥ 80 kg)",
        "4. Chirurgie colorectale: céfazoline 2g + métronidazole 500mg",
        "5. Chirurgie urologique: céfazoline 2g ou ciprofloxacine 400mg selon ECBU",
        "6. Allergie pénicillines: clindamycine 600mg + gentamicine 5 mg/kg",
        "7. Réinjection: céfazoline toutes les 4h si chirurgie > 4h ou pertes > 1500 mL",
        "8. Durée maximale: dose unique (sauf exceptions: cardio, prothèse)",
        "9. Documenter heure d'injection dans le dossier anesthésique"
      ],
      "en": [
        "1. Identify surgery type (clean, clean-contaminated, contaminated)",
        "2. Inject 30-60 minutes before incision (ideally at induction)",
        "3. Standard clean surgery: cefazolin 2g IV (3g if ≥ 80 kg)",
        "4. Colorectal surgery: cefazolin 2g + metronidazole 500mg",
        "5. Urologic surgery: cefazolin 2g or ciprofloxacin 400mg per urine culture",
        "6. Penicillin allergy: clindamycin 600mg + gentamicin 5 mg/kg",
        "7. Redosing: cefazolin every 4h if surgery > 4h or blood loss > 1500 mL",
        "8. Maximum duration: single dose (exceptions: cardiac, prosthetic)",
        "9. Document injection time in anesthetic record"
      ],
      "pt": [
        "1. Identificar tipo de cirurgia (limpa, limpa-contaminada, contaminada)",
        "2. Injeção 30-60 minutos antes da incisão (idealmente na indução)",
        "3. Cirurgia limpa standard: cefazolina 2g IV (3g se ≥ 80 kg)",
        "4. Cirurgia colorretal: cefazolina 2g + metronidazol 500mg",
        "5. Cirurgia urológica: cefazolina 2g ou ciprofloxacina 400mg conforme urocultura",
        "6. Alergia a penicilinas: clindamicina 600mg + gentamicina 5 mg/kg",
        "7. Readministração: cefazolina a cada 4h se cirurgia > 4h ou perdas > 1500 mL",
        "8. Duração máxima: dose única (exceções: cardíaca, prótese)",
        "9. Documentar hora da injeção no processo anestésico"
      ]
    },
    "references": [{ "source": "SFAR RFE Antibioprophylaxie", "year": 2018 }]
  },
  {
    "id": "thromboprophylaxis-protocol",
    "category": "preop",
    "titles": {
      "fr": "Protocole de thromboprophylaxie",
      "en": "Thromboprophylaxis Protocol",
      "pt": "Protocolo de tromboprofilaxia"
    },
    "steps": {
      "fr": [
        "1. Évaluer le risque thromboembolique (score de Caprini ou SFAR)",
        "2. Risque faible: mobilisation précoce seule",
        "3. Risque modéré: HBPM (énoxaparine 40 mg/j SC) débutée 6-12h post-op",
        "4. Risque élevé: HBPM dose adaptée + bas de contention classe 2",
        "5. PTH/PTG: prophylaxie 10-14 jours (HBPM ou rivaroxaban)",
        "6. Fracture col fémoral: prophylaxie 35 jours",
        "7. Chirurgie carcinologique majeure: prophylaxie 28 jours",
        "8. Contre-indications HBPM: compression pneumatique intermittente",
        "9. Vérifier plaquettes si HBPM > 5 jours (risque TIH)",
        "10. Documenter la stratégie dans le dossier"
      ],
      "en": [
        "1. Assess thromboembolic risk (Caprini score or similar)",
        "2. Low risk: early mobilization only",
        "3. Moderate risk: LMWH (enoxaparin 40 mg/day SC) starting 6-12h post-op",
        "4. High risk: adjusted-dose LMWH + class 2 compression stockings",
        "5. THR/TKR: prophylaxis 10-14 days (LMWH or rivaroxaban)",
        "6. Hip fracture: prophylaxis 35 days",
        "7. Major cancer surgery: prophylaxis 28 days",
        "8. LMWH contraindications: intermittent pneumatic compression",
        "9. Check platelets if LMWH > 5 days (HIT risk)",
        "10. Document strategy in medical record"
      ],
      "pt": [
        "1. Avaliar risco tromboembólico (score de Caprini ou similar)",
        "2. Risco baixo: mobilização precoce apenas",
        "3. Risco moderado: HBPM (enoxaparina 40 mg/dia SC) iniciada 6-12h pós-op",
        "4. Risco alto: HBPM dose ajustada + meias de compressão classe 2",
        "5. PTA/PTJ: profilaxia 10-14 dias (HBPM ou rivaroxabano)",
        "6. Fratura do colo do fémur: profilaxia 35 dias",
        "7. Cirurgia oncológica major: profilaxia 28 dias",
        "8. Contra-indicações HBPM: compressão pneumática intermitente",
        "9. Verificar plaquetas se HBPM > 5 dias (risco TIH)",
        "10. Documentar a estratégia no processo"
      ]
    },
    "references": [
      { "source": "SFAR RFE Thromboprophylaxie", "year": 2019 },
      { "source": "ACCP Guidelines", "year": 2021 }
    ]
  },
  {
    "id": "transfusion-protocol",
    "category": "emergency",
    "titles": {
      "fr": "Protocole transfusionnel",
      "en": "Transfusion Protocol",
      "pt": "Protocolo transfusional"
    },
    "steps": {
      "fr": [
        "1. Vérifier indication: Hb < 7 g/dL (sain), < 8-9 g/dL (coronarien/âgé)",
        "2. Vérifier groupe sanguin + RAI (validité < 72h)",
        "3. Commander produits sanguins labiles au dépôt",
        "4. Contrôle ultime au lit du patient (CUSP): identité + concordance",
        "5. Régler débit: 1 CGR en 30-60 min (sauf urgence vitale)",
        "6. Surveiller les 15 premières minutes (réaction hémolytique immédiate)",
        "7. Monitorage: température, PA, FC, signes de réaction transfusionnelle",
        "8. En cas de réaction: ARRÊTER la transfusion, prélever hémocultures + bilan hémolytique",
        "9. Documentation: traçabilité dans le dossier (numéro PSL, heure début/fin)",
        "10. NFS de contrôle 1h après la fin de la transfusion"
      ],
      "en": [
        "1. Verify indication: Hb < 7 g/dL (healthy), < 8-9 g/dL (coronary disease/elderly)",
        "2. Verify blood group + antibody screen (valid < 72h)",
        "3. Order blood products from blood bank",
        "4. Bedside compatibility check: identity + crossmatch verification",
        "5. Set rate: 1 RBC unit in 30-60 min (unless life-threatening)",
        "6. Monitor first 15 minutes (immediate hemolytic reaction)",
        "7. Monitoring: temperature, BP, HR, signs of transfusion reaction",
        "8. If reaction: STOP transfusion, blood cultures + hemolysis workup",
        "9. Documentation: traceability in record (product number, start/end time)",
        "10. CBC control 1h after transfusion completion"
      ],
      "pt": [
        "1. Verificar indicação: Hb < 7 g/dL (saudável), < 8-9 g/dL (coronário/idoso)",
        "2. Verificar grupo sanguíneo + pesquisa de anticorpos (validade < 72h)",
        "3. Requisitar produtos sanguíneos ao serviço de sangue",
        "4. Controlo final à cabeceira: identidade + concordância",
        "5. Regular débito: 1 CE em 30-60 min (salvo urgência vital)",
        "6. Vigiar os primeiros 15 minutos (reação hemolítica imediata)",
        "7. Monitorização: temperatura, PA, FC, sinais de reação transfusional",
        "8. Em caso de reação: PARAR transfusão, hemoculturas + estudo hemolítico",
        "9. Documentação: rastreabilidade no processo (número PSL, hora início/fim)",
        "10. Hemograma de controlo 1h após o fim da transfusão"
      ]
    },
    "references": [{ "source": "SFAR RFE Transfusion", "year": 2019 }]
  }
]
